Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 15 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| International Stem Cell Corporation (QB) | ISCO | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.09 | 05:25:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.09 | 0.09 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 3 | 15 | - | 0.046 - 0.167 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 13:43:56 | 7 | US$ 0.0957 | USD |
International Stem Cell Corporation (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 720.4k | 8.00M | 2.19M | 7.79M | -131k | -0.02 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
International Stem Cell (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/14/2024 | 15:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/13/2023 | 15:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/08/2023 | 12:18 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/08/2023 | 12:17 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 9/27/2023 | 11:27 | Edgar (US Regulatory) | Form DEF 14C - Other definitive information statements |
| 9/18/2023 | 07:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/11/2023 | 13:20 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ISCO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.09 | 0.109 | 0.09 | 0.1056777 | 1,114 | 0.00 | 0.00% |
| 1 Month | 0.08 | 0.109 | 0.0612 | 0.1037811 | 1,787 | 0.01 | 12.50% |
| 3 Months | 0.105 | 0.12 | 0.0521 | 0.0924166 | 1,963 | -0.015 | -14.29% |
| 6 Months | 0.112 | 0.1295 | 0.046 | 0.0932879 | 2,688 | -0.022 | -19.64% |
| 1 Year | 0.1542 | 0.167 | 0.046 | 0.1158589 | 3,125 | -0.0642 | -41.63% |
| 3 Years | 0.40 | 0.80 | 0.046 | 0.3872056 | 5,373 | -0.31 | -77.50% |
| 5 Years | 1.03 | 1.20 | 0.046 | 0.5076156 | 5,603 | -0.94 | -91.26% |
International Stem Cell (QB) Description
| International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). |
